Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

L0376000

Leuprorelin

European Pharmacopoeia (EP) Reference Standard

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C59H84N16O12
Numéro CAS:
53714-56-0
Poids moléculaire :
1209.40
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

leuprorelin

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

InChI

1S/C57H80N16O12.C2H4O2/c1-6-61-53(82)44-14-10-22-73(44)56(85)39(13-9-21-62-57(58)59)66-54(83)46(30(2)3)72-55(84)47(31(4)5)71-51(80)40(23-32-15-17-35(75)18-16-32)67-52(81)43(28-74)70-49(78)41(24-33-26-63-37-12-8-7-11-36(33)37)68-50(79)42(25-34-27-60-29-64-34)69-48(77)38-19-20-45(76)65-38;1-2(3)4/h7-8,11-12,15-18,26-27,29-31,38-44,46-47,63,74-75H,6,9-10,13-14,19-25,28H2,1-5H3,(H,60,64)(H,61,82)(H,65,76)(H,66,83)(H,67,81)(H,68,79)(H,69,77)(H,70,78)(H,71,80)(H,72,84)(H4,58,59,62);1H3,(H,3,4)/t38?,39-,40-,41-,42-,43?,44-,46-,47+;/m0./s1

Clé InChI

ATCUBNJYGKGZGL-GZROYGCLSA-N

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the Issuing Pharmacopoeia.

For further information and support please go to the website of the issuing Pharmacopoeia.

It is a synthetic nonapeptide analogue of the hypothalamic peptide, gonadorelin. It is obtained by chemical synthesis and is available as an acetate.

Application

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia. Their suitability for any other use is not guaranteed and is the sole responsibility of the user. This standard is not intended for human or animal use.
Established for the preparation of reference solutions (a) in the assay and testing of related substances of leuprorelin using liquid chromatography (General text 2.2.29), according to the monograph 1442 of European Pharmacopeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Leuprorelin
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 3073-3074 (2008)
R Berges et al.
Current medical research and opinion, 22(4), 649-655 (2006-05-11)
Leuprorelin is a well known luteinising hormone releasing hormone (LHRH) agonist. The drug is effective in the treatment of advanced prostate cancer and is well tolerated. This article reviews published literature (based on a search of PubMed, EMBASE and Biosis
Piero Periti et al.
Clinical pharmacokinetics, 41(7), 485-504 (2002-06-27)
Leuprorelin acetate is a synthetic agonist analogue of gonadotropin-releasing hormone. Continued leuprorelin administration results in suppression of gonadal steroid synthesis, resulting in pharmacological castration. Since leuprorelin is a peptide, it is orally inactive and generally given subcutaneously or intramuscularly. Sustained
Michael T Schweizer et al.
Cancer, 119(20), 3610-3618 (2013-08-15)
The current trial evaluated 2 common therapies for patients with advanced prostate cancer, docetaxel and hormonal therapy (HT), in the surgical adjuvant setting. TAX-3501 was a randomized, phase 3, adjuvant study post-radical prostatectomy (RP) in high-risk patients with prostate cancer
Gina Lama et al.
PloS one, 8(1), e52530-e52530 (2013-01-18)
High cell-surface GnRH receptor (GnRH-R) levels have been shown to have a major influence on the extent of GnRH agonist-mediated tumor growth inhibition. The ability of the GnRH agonist leuprorelin acetate (LA) to induce a post-transcriptional upregulation of GnRH-R at
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique